An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer, Early Breast Cancer
Interventions: DRUG: Camizestrant|DRUG: Tamoxifen|DRUG: Anastrozole|DRUG: Letrozole|DRUG: Exemestane|DRUG: Abemaciclib
Sponsor: AstraZeneca
Collaborators: Austrian Breast and Colorectal Cancer Study Group (ABCSG)